p38MAPK信号转导通路在七氟烷后处理减轻乳鼠心肌细胞缺氧复氧损伤中的作用

Objective To evalnate the role of p38 mitogen-activated protein kinase (p38MAPK) signal pathway in the protective effect of sevoflurane postconditioning (S-Postcon) on cultured neonatal rat cardiomyocytes against anoxia/reoxygenation (A/R) injury. Methods Primary cultured neonatal rat cardiomyocytes were randomly divided into 7 groups: group Ⅰ normal control (C); group Ⅱ A/R; group Ⅲ S-Poatcan + A/R; group ⅣS-Postcon + SB203580 + A/R; group Ⅴ S-Postcon + DMSO + A/R; group Ⅵ SB203580 + A/R and group Ⅶ DMSO + A/R. GroupⅡ-Ⅶ were exposed to 2 h anoxia (95% N2-5% CO2) followed by 1 h reoxygenation. In group Ⅲ, Ⅳ and Ⅴ the cultured myocytes were postconditioned with 20 min 3% sevoflurane in 97% O2 alone (in group Ⅲ) or in conjunction with 5 μmol/L 5B203580 (a specific p38 MAPK inhibitor) (in group Ⅳ) or 0.1% DMSO (in group Ⅴ) followed by 40 min reoxygenation. The cardiomyocytes were reoxygenated in the presence of 5 μmol/L SB203580 in group Ⅵ or 0.1% DMSO in group Ⅶ. The LDH activity, cell survival rate and apoptotic rate were measured at the end of the experiment. The levels of phosphor-p38MAPK (p-p38MAPK) was detected by Western blotting. Results S-Postcon reduced LDH activity and apoptotic rate and increased cell survival rate and the level of p-p38MAPK as compared with group A/R (group Ⅱ). The myocardial protecfive effect of S-Posteon was eliminated by p38MAPK inhibltor-SB203580 and p-p38MAPK level was also decreased at the same time.Conclusion Sevoflurane postconditioning can attenuate anoxia/reoxygenation induced cardiomyocyte injury through activation of p38MAPK signal pathway.     

MLK3-MKK3/6-p38MAPK信号转导通路在大鼠内毒素性急性肺损伤中的作用

目的 探讨MLK3-MKK3/6-p38MAPK信号转导通路在大鼠内毒素性急性肺损伤中的作用.方法 健康成年雄性SD大鼠78只,体重200～250 g,随机分为4组:对照组(C组,n=6)、急性肺损伤组(ALI组,n=24)、MLK3抑制剂K252a组(MK组,n=24)和p38MAPK特异性抑制剂SB203580组(MS组,n=24).ALI组尾静脉注射内毒素5 mg/kg制备大鼠急性肺损伤模型,C组给予等容量生理盐水,MK组和MS组于注射内毒素前30 min经尾静脉分别注射K252a 75μg/kg、SB203580 10 mg/kg.ALI组、MK组和MS组于注射内毒素后1、3、6、12 h(1-4)时各组随机取6只大鼠,C组于给予生理盐水后即刻处死取肺,采用ELISA法测定支气管肺泡灌洗液中TNF-α浓度,称重后计算肺湿干重比,采用Western b1ot法测定p-MLK3、p-MKK3/6及p-p38MAPK的表达,观察肺组织病理学结果.结果 与C组比较,ALI组、MK组和MS组各时点支气管肺泡灌洗液中TNF-α浓度、肺湿干重比、p-MLK3、p-MKK3/6及p-p38MAPK的表达水平升高(P＜0.01);与ALI组比较,MK组上述指标降低,MS组支气管肺泡灌洗液中TNF-α浓度、肺湿干重比、p-p38MAPK表达水平降低(P＜0.05).病理学结果显示:MK组和MS组肺组织损伤较ALI组减轻.结论 MLK3-MKK3/6-p38MAPK信号转导通路在大鼠内毒素性急性肺损伤中起重要作用.     

c-Jun氨基末端激酶在大鼠内毒素性急性肺损伤中的作用

目的 评价c-Jun氨基末端激酶(JNK)在大鼠内毒素性急性肺损伤中的作用.方法 雄性成年SD大鼠80只,体重250～300 g,采用随机数字表法,将其随机分为4组(n=20):对照组(C组)、急性肺损伤组(ALI组)、SP600125组(S组)和二甲基亚砜组(D组).ALI组、S组和D组尾静脉注射LPS 5 mg/kg,C组尾静脉注射等容量生理盐水;S组和D组给予LPS后,分别尾静脉注射JNK抑制剂SP600125 30 mg/kg或二甲基亚砜0.2 ml.于给予LPS后4 h时,各组处死10只大鼠,回收支气管肺泡灌洗液(BALF)并取肺组织,采用ELISA法检测BALF中TNF-α和IL-1β的浓度,计算肺组织湿重/干重比(W/D比),观察肺组织病理学结果,并进行肺损伤评分.各组其余10只大鼠观察至给予LPS后48 h,记录大鼠生存情况.结果 与C组比较,其余各组BALF中TNF-α和IL-1β的浓度、肺组织W/D比和肺损伤评分升高,生存率降低(P<0.05或0.01);与ALI组比较,S组BALF中TNF-α和IL-1度、肺组织W/D比和肺损伤评分降低,生存率升高(P<0.01),D组差异无统计学意义(P>0.05).结论 JNK的活化参与了大鼠内毒素性急性肺损伤的发生发展.

Abstract：

Objective To evaluate the role of c-Jun N-terminal kinase (JNK) in lipopolysaccharide (LPS)-induced acute lung injury ( ALI) in rats.Methods Eighty male SD rats weighing 250-300 g were randomly divided into 4 groups ( n = 20 each) : control group (group C) ; ALI group; LPS + SP600125 (JNK inhibitor)group (group S) and LPS+ DMSO (the solvent) group (group DMSO) . ALI was induced by intravenous LPS 5mg/kg. In S and DMSO groups, SP600125 30 mg/kg and DMSO 0.2 ml were injected intravenously after LPS administration respectively. Ten animals were sacrificed by exsanguinafions at 4 h after LPS administration in each group. The broncho-alveolar lavage fluid (BALF) was colleted. The TNF-α and IL-1β concentrations in BALF were measured. The lungs were removed for microscopic examination and determination of W/D lung weight ratio. The other 10 animals in each group were observed for 48 h survival rate. Results Intravenous LPS significantly increased TNF-α and IL-1β concentrations in BALF and W/D lung weight ratio, decreased 48 h survival rate and induced histologic damage. Intravenous SP600125 30 mg/kg significantly attenuated the above-mentioned LPS-induced changes. Conclusion Activation of JNK is involved in the development of endotoxin-induced ALI in rats.     

罗格列酮对多囊肾囊肿衬里上皮细胞p38促分裂原活化蛋白激酶信号通路的影响

Objective To investigate the effect of rosiglitazone on p38 mitogen-activated protein kinase (p38MAPK) pathway in polycystic kidney cyst-lining epithelial cells. Methods The cyst-lining epithelial cells (PKD cells) from human polycystic kidney were treated with rosiglitazone (10 μmol/L), peroxisome proliferator-activated receptor-γ (PPARγ) inhibitor GW9662 (10 μmol/L), rosiglitazone (10 μmol/L) +GW9662 (10 μmol/L), p38MAPK specific inhibitor SB203580 (10 μmol/L), SB203580 (10 μmol/L)+ rosiglitazone(10 μmol/L) for 2 hours followed by epidermal growth factor (EGF) stimulation. Protein expressions of p38, phuspho-p38 (p-p38) and proliferating cell nuclear antigen (PCNA) were detected by Western blot. p38 mRNA was examined by RT-PCR. Expression of c-fos and c-jun was observed by immunocytochemistry. Results (1) EGF markedly up-regulated the expressions of p38, p-p38, PCNA, c-fos anti c-jun compared with control group (P<0.01). (2) Compared with EGF treated group, rosiglitazone significantly reduced p38 activation and mRNA expression (P<0.01, respectively). Rosiglitazone, rosiglitazone+SB203580 could significantly down-regulated p-p38, PCNA, c-fos and c-jun expression (P<0.01, respectively) with no significant difference between these two groups. (3) GW9662 partially reversed the reduction effect of rosiglitazone. Conclusions Rosiglitazone can inhibit proliferation of autosomal dominant polycystic kidney disease cyst-lining epithelial cells partially through down-regulating p38 activation and reducing c-fos, c-jun and PCNA expression. The above effect of rosiglitazone is in part PPARγ-independcnt.     

罗格列酮对多囊肾囊肿衬里上皮细胞p38促分裂原活化蛋白激酶信号通路的影响

Objective To investigate the effect of rosiglitazone on p38 mitogen-activated protein kinase (p38MAPK) pathway in polycystic kidney cyst-lining epithelial cells. Methods The cyst-lining epithelial cells (PKD cells) from human polycystic kidney were treated with rosiglitazone (10 μmol/L), peroxisome proliferator-activated receptor-γ (PPARγ) inhibitor GW9662 (10 μmol/L), rosiglitazone (10 μmol/L) +GW9662 (10 μmol/L), p38MAPK specific inhibitor SB203580 (10 μmol/L), SB203580 (10 μmol/L)+ rosiglitazone(10 μmol/L) for 2 hours followed by epidermal growth factor (EGF) stimulation. Protein expressions of p38, phuspho-p38 (p-p38) and proliferating cell nuclear antigen (PCNA) were detected by Western blot. p38 mRNA was examined by RT-PCR. Expression of c-fos and c-jun was observed by immunocytochemistry. Results (1) EGF markedly up-regulated the expressions of p38, p-p38, PCNA, c-fos anti c-jun compared with control group (P<0.01). (2) Compared with EGF treated group, rosiglitazone significantly reduced p38 activation and mRNA expression (P<0.01, respectively). Rosiglitazone, rosiglitazone+SB203580 could significantly down-regulated p-p38, PCNA, c-fos and c-jun expression (P<0.01, respectively) with no significant difference between these two groups. (3) GW9662 partially reversed the reduction effect of rosiglitazone. Conclusions Rosiglitazone can inhibit proliferation of autosomal dominant polycystic kidney disease cyst-lining epithelial cells partially through down-regulating p38 activation and reducing c-fos, c-jun and PCNA expression. The above effect of rosiglitazone is in part PPARγ-independcnt.     

罗格列酮对多囊肾囊肿衬里上皮细胞p38促分裂原活化蛋白激酶信号通路的影响

Objective To investigate the effect of rosiglitazone on p38 mitogen-activated protein kinase (p38MAPK) pathway in polycystic kidney cyst-lining epithelial cells. Methods The cyst-lining epithelial cells (PKD cells) from human polycystic kidney were treated with rosiglitazone (10 μmol/L), peroxisome proliferator-activated receptor-γ (PPARγ) inhibitor GW9662 (10 μmol/L), rosiglitazone (10 μmol/L) +GW9662 (10 μmol/L), p38MAPK specific inhibitor SB203580 (10 μmol/L), SB203580 (10 μmol/L)+ rosiglitazone(10 μmol/L) for 2 hours followed by epidermal growth factor (EGF) stimulation. Protein expressions of p38, phuspho-p38 (p-p38) and proliferating cell nuclear antigen (PCNA) were detected by Western blot. p38 mRNA was examined by RT-PCR. Expression of c-fos and c-jun was observed by immunocytochemistry. Results (1) EGF markedly up-regulated the expressions of p38, p-p38, PCNA, c-fos anti c-jun compared with control group (P<0.01). (2) Compared with EGF treated group, rosiglitazone significantly reduced p38 activation and mRNA expression (P<0.01, respectively). Rosiglitazone, rosiglitazone+SB203580 could significantly down-regulated p-p38, PCNA, c-fos and c-jun expression (P<0.01, respectively) with no significant difference between these two groups. (3) GW9662 partially reversed the reduction effect of rosiglitazone. Conclusions Rosiglitazone can inhibit proliferation of autosomal dominant polycystic kidney disease cyst-lining epithelial cells partially through down-regulating p38 activation and reducing c-fos, c-jun and PCNA expression. The above effect of rosiglitazone is in part PPARγ-independcnt.     

罗格列酮对多囊肾囊肿衬里上皮细胞p38促分裂原活化蛋白激酶信号通路的影响

Objective To investigate the effect of rosiglitazone on p38 mitogen-activated protein kinase (p38MAPK) pathway in polycystic kidney cyst-lining epithelial cells. Methods The cyst-lining epithelial cells (PKD cells) from human polycystic kidney were treated with rosiglitazone (10 μmol/L), peroxisome proliferator-activated receptor-γ (PPARγ) inhibitor GW9662 (10 μmol/L), rosiglitazone (10 μmol/L) +GW9662 (10 μmol/L), p38MAPK specific inhibitor SB203580 (10 μmol/L), SB203580 (10 μmol/L)+ rosiglitazone(10 μmol/L) for 2 hours followed by epidermal growth factor (EGF) stimulation. Protein expressions of p38, phuspho-p38 (p-p38) and proliferating cell nuclear antigen (PCNA) were detected by Western blot. p38 mRNA was examined by RT-PCR. Expression of c-fos and c-jun was observed by immunocytochemistry. Results (1) EGF markedly up-regulated the expressions of p38, p-p38, PCNA, c-fos anti c-jun compared with control group (P<0.01). (2) Compared with EGF treated group, rosiglitazone significantly reduced p38 activation and mRNA expression (P<0.01, respectively). Rosiglitazone, rosiglitazone+SB203580 could significantly down-regulated p-p38, PCNA, c-fos and c-jun expression (P<0.01, respectively) with no significant difference between these two groups. (3) GW9662 partially reversed the reduction effect of rosiglitazone. Conclusions Rosiglitazone can inhibit proliferation of autosomal dominant polycystic kidney disease cyst-lining epithelial cells partially through down-regulating p38 activation and reducing c-fos, c-jun and PCNA expression. The above effect of rosiglitazone is in part PPARγ-independcnt.     

罗格列酮对多囊肾囊肿衬里上皮细胞p38促分裂原活化蛋白激酶信号通路的影响

Objective To investigate the effect of rosiglitazone on p38 mitogen-activated protein kinase (p38MAPK) pathway in polycystic kidney cyst-lining epithelial cells. Methods The cyst-lining epithelial cells (PKD cells) from human polycystic kidney were treated with rosiglitazone (10 μmol/L), peroxisome proliferator-activated receptor-γ (PPARγ) inhibitor GW9662 (10 μmol/L), rosiglitazone (10 μmol/L) +GW9662 (10 μmol/L), p38MAPK specific inhibitor SB203580 (10 μmol/L), SB203580 (10 μmol/L)+ rosiglitazone(10 μmol/L) for 2 hours followed by epidermal growth factor (EGF) stimulation. Protein expressions of p38, phuspho-p38 (p-p38) and proliferating cell nuclear antigen (PCNA) were detected by Western blot. p38 mRNA was examined by RT-PCR. Expression of c-fos and c-jun was observed by immunocytochemistry. Results (1) EGF markedly up-regulated the expressions of p38, p-p38, PCNA, c-fos anti c-jun compared with control group (P<0.01). (2) Compared with EGF treated group, rosiglitazone significantly reduced p38 activation and mRNA expression (P<0.01, respectively). Rosiglitazone, rosiglitazone+SB203580 could significantly down-regulated p-p38, PCNA, c-fos and c-jun expression (P<0.01, respectively) with no significant difference between these two groups. (3) GW9662 partially reversed the reduction effect of rosiglitazone. Conclusions Rosiglitazone can inhibit proliferation of autosomal dominant polycystic kidney disease cyst-lining epithelial cells partially through down-regulating p38 activation and reducing c-fos, c-jun and PCNA expression. The above effect of rosiglitazone is in part PPARγ-independcnt.     

罗格列酮对多囊肾囊肿衬里上皮细胞p38促分裂原活化蛋白激酶信号通路的影响

Objective To investigate the effect of rosiglitazone on p38 mitogen-activated protein kinase (p38MAPK) pathway in polycystic kidney cyst-lining epithelial cells. Methods The cyst-lining epithelial cells (PKD cells) from human polycystic kidney were treated with rosiglitazone (10 μmol/L), peroxisome proliferator-activated receptor-γ (PPARγ) inhibitor GW9662 (10 μmol/L), rosiglitazone (10 μmol/L) +GW9662 (10 μmol/L), p38MAPK specific inhibitor SB203580 (10 μmol/L), SB203580 (10 μmol/L)+ rosiglitazone(10 μmol/L) for 2 hours followed by epidermal growth factor (EGF) stimulation. Protein expressions of p38, phuspho-p38 (p-p38) and proliferating cell nuclear antigen (PCNA) were detected by Western blot. p38 mRNA was examined by RT-PCR. Expression of c-fos and c-jun was observed by immunocytochemistry. Results (1) EGF markedly up-regulated the expressions of p38, p-p38, PCNA, c-fos anti c-jun compared with control group (P<0.01). (2) Compared with EGF treated group, rosiglitazone significantly reduced p38 activation and mRNA expression (P<0.01, respectively). Rosiglitazone, rosiglitazone+SB203580 could significantly down-regulated p-p38, PCNA, c-fos and c-jun expression (P<0.01, respectively) with no significant difference between these two groups. (3) GW9662 partially reversed the reduction effect of rosiglitazone. Conclusions Rosiglitazone can inhibit proliferation of autosomal dominant polycystic kidney disease cyst-lining epithelial cells partially through down-regulating p38 activation and reducing c-fos, c-jun and PCNA expression. The above effect of rosiglitazone is in part PPARγ-independcnt.     

罗格列酮对多囊肾囊肿衬里上皮细胞p38促分裂原活化蛋白激酶信号通路的影响

Objective To investigate the effect of rosiglitazone on p38 mitogen-activated protein kinase (p38MAPK) pathway in polycystic kidney cyst-lining epithelial cells. Methods The cyst-lining epithelial cells (PKD cells) from human polycystic kidney were treated with rosiglitazone (10 μmol/L), peroxisome proliferator-activated receptor-γ (PPARγ) inhibitor GW9662 (10 μmol/L), rosiglitazone (10 μmol/L) +GW9662 (10 μmol/L), p38MAPK specific inhibitor SB203580 (10 μmol/L), SB203580 (10 μmol/L)+ rosiglitazone(10 μmol/L) for 2 hours followed by epidermal growth factor (EGF) stimulation. Protein expressions of p38, phuspho-p38 (p-p38) and proliferating cell nuclear antigen (PCNA) were detected by Western blot. p38 mRNA was examined by RT-PCR. Expression of c-fos and c-jun was observed by immunocytochemistry. Results (1) EGF markedly up-regulated the expressions of p38, p-p38, PCNA, c-fos anti c-jun compared with control group (P<0.01). (2) Compared with EGF treated group, rosiglitazone significantly reduced p38 activation and mRNA expression (P<0.01, respectively). Rosiglitazone, rosiglitazone+SB203580 could significantly down-regulated p-p38, PCNA, c-fos and c-jun expression (P<0.01, respectively) with no significant difference between these two groups. (3) GW9662 partially reversed the reduction effect of rosiglitazone. Conclusions Rosiglitazone can inhibit proliferation of autosomal dominant polycystic kidney disease cyst-lining epithelial cells partially through down-regulating p38 activation and reducing c-fos, c-jun and PCNA expression. The above effect of rosiglitazone is in part PPARγ-independcnt.     

p38MAPK/iNOS/HO-1信号通路在赤芍减轻大鼠内毒素性急性肺损伤中的作用

目的 评价p38MAPK/iNOS/HO-1信号通路在赤芍减轻大鼠内毒素性急性肺损伤(AL1)中的作用.方法 健康清洁级雄性Wistar大鼠40只,随机分为5组(n=8):生理盐水对照组(C组)、内毒素组(L组)、赤芍组(R组)、赤芍预处理组(PR组)和SB203580组(S组).气管内滴注脂多糖(LPS)制备大鼠ALI模型.L组气管内滴注1 ml LPS溶液(2.5 mg/kg);C组滴注等容量生理盐水;R组、PR组分别于气管内滴注LPS后、滴注前2 h,经股静脉输注赤芍注射液15 mg·kg-1·h-1 2 h;S组于气管内滴注LPS前3 h,经股静脉输注SB203580溶液2.5 μmol·kg-1·h-1 3 h.于气管内滴注LPS后6 h时,经颈动脉采血样2 ml,行血气分析及测定血清NO浓度;颈动脉放血处死大鼠,测定支气管肺泡灌洗液蛋白浓度,计数中性粒细胞及细胞总数,检测肺组织MDA含量,p38MAPK、HO-1及iNOS的表达.观察肺组织病理学结果 .结果 与C组比较,其余各组肺组织p38MAPK、iNOS及HO-1表达上调,支气管肺泡灌洗液中性粒细胞计数比、蛋白浓度、肺组织MDA含量及血清NO浓度升高.PaO2和HCO1浓度降低(P<0.01);与L组比较,R组、PR组和S组p38MAPK及iNOS表达下调,HO-1表达上调.支气管肺泡灌洗液中性粒细胞计数比、蛋白浓度、肺组织MDA含量及血清NO浓度降低,PaO2和HCO3-升高(P<0.05);R组、PR组和S组肺组织损伤程度较L组减轻.结论 赤芍可减轻大鼠内毒素性急性肺损伤,可能与抑制p38MAPK/iNOS/HO-1信号通路有关.     

p38丝裂原活化蛋白激酶在全脑缺血再灌注损伤大鼠海马神经元DNA修复中的作用

目的 探讨p38丝裂原活化蛋白激酶(p38 MAPK)在全脑缺血再灌注损伤大鼠海马神经元DNA修复中的作用.方法 清洁级雄性SD大鼠108只,采用四血管阻断法建立大鼠全脑缺血再灌注模型,随机分为3组(n=36):假手术组(S组)仅暴露双侧颈总动脉和椎动脉;缺血再灌注组(IR组)侧脑室注射1%DMSO溶液5μl,30 min后行全脑缺血再灌注;p38 MAPK抑制剂SB203580干预组(SB组)侧脑室注射SB203580溶液5 μl(溶于1%DMSO溶液),30 min后行全脑缺血再灌注.分别于再灌注2、6、12、24、48和72 h时各组处死6只大鼠,提取海马组织观察神经元病理学结果,计算神经元凋亡指数(AI),测定磷酸化的p38 MAPK蛋白及Ku70蛋白表达水平.结果 与S组比较,IR组和SB组各时点AI升高,p-p38 MAPK蛋白表达上调,p-Ku70蛋白表达下调(P(0.05或0.01),病理损伤明显;与IR组比较,SB组各时点AI降低,p-p38 MAPK蛋白表达下调,p-Ku70蛋白表达上调(P<0.01),病理损伤程度减轻.结论 p38 MAPK可能通过下调DNA修复酶Ku70蛋白的表达,使海马神经元DNA修复功能受损,导致神经元凋亡,参与全脑缺血再灌注损伤.     

糖皮质激素受体对内毒素性急性肺损伤大鼠的保护作用及机制

目的 探讨糖皮质激素受体(glucocorticoid receptor,GR)在内毒素急性肺损伤(acute lung injury,ALI)中的作用及机制.方法 SD雄性大鼠84只,随机数字表法分为5组:Control组,仅注射生理盐水;脂多糖(lipopoIysaccharide,LPS)组,经尾静脉注射LPS 5 mg/kg;地塞米松(dexamethasone,DEX)+LPS组,注射LPS前30 min腹腔注射Dex 6 mg/kg;米非司酮(RU486)组,皮下注射GR拮抗剂RU486 20 mg/kg,90 min后经尾静脉注射生理盐水;RU486+Dex+LPS组,按照上述顺序分别注射RU486、Dex和LPS.Control组和RU486组6 h后,其余3组分别在1、3、6 h各时间点处死.检测各组大鼠支气管肺泡灌洗液(brobehoalveolar lavage fluid,BALF)中蛋白浓度,肺水系数(1ung index,LI),肺组织的病理变化,凋亡指数(apoptosis index,AI)以及肺组织中p38MAPK的活化状态及表达.结果 与Control组BALF中蛋白浓度(49±5)g/L、LI(2.36±0.14)、AI(12.0±1.7)%相比,LPS组分别为(77±9)g/L、5.93±0.44、(43.9±3.1)%(P＜0.05),HE染色显示肺组织炎症和损伤严重.与LPS组相比,Dex+LPS组分别为(54±4)g/L、3.77±0.48、(32.7±2.7)%(P＜0.05),且肺组织损伤程度减轻,应用GR抑制剂RU486后,Dex的肺保护作用消失.另外,LPS组肺组织中磷酸化p38MAPK(p-p38MAPK)的表达与Control组相比显著升高(P＜0.05);与LPS相比,Dex+LPS组p-p38MAPK表达下调(P＜0.05),而RU486+Dex+LPS组的表达上调(P＞0.05).结论 糖皮质激素受体在内毒素导致的急性肺损伤中发挥着重要的作用.激素活化的GR可能通过抑制p38MAPK的活化/磷酸化抑制肺组织细胞的凋亡,缓解肺损伤的程度.     

p38MAPK信号转导通路在七氟烷后处理减轻乳鼠心肌细胞缺氧复氧损伤中的作用

目的 评价p38丝裂原活化蛋白激酶(p38MAPK)信号转导通路在七氟烷后处理减轻乳鼠心肌细胞缺氧复氧损伤中的作用.方法 健康新生SD大鼠,日龄1～3 d,处死后取心室肌组织,培养心肌细胞,随机分为7组:对照组(C组)于CO2培养箱中持续培养3 h;缺氧复氧组(AR组)细胞缺氧2 h,复氧1 h;七氟烷后处理组(SP组)细胞缺氧2 h,复氧开始即刻更换为3%七氟烷饱和的DMEM培养液,孵育20 min,再更换为无血清DMEM培养液,继续复氧40 min;七氟烷后处理+SB203580组(SP+SB组)于七氟烷后处理同时加入SB203580(p38MAPK特异性抑制剂)至5 μmol/L,孵育20 min;七氟烷后处理+二甲亚砜组(SP+DMSO组)于七氟烷后处理同时加入0.1%DMSO,孵育20 min;SB203580组(SB组)于复氧开始时加入SB203580至5 μmol/L,孵育20 min;二甲亚砜组(DMSO组)于复氧开始即刻加入0.1%DMSO,孵育20 min.各组细胞分别接种于24孔培养板(1 ml/孔)、35 mm培养皿(5 mlnd/皿)和50 ml培养瓶(8 ml/瓶)中,每组12孔、6皿和6瓶.于复氧结束后,采用比色法测定细胞培养液乳酸脱氢酶(LDH)活性;采用台盼蓝排斥实验测定细胞存活率;采用流式细胞仪测定细胞凋亡率;采用Western blot法测定磷酸化p38MAPK(p-p38MAPK)表达水平.结果 与C组比较,其余各组LDH活性升高,细胞存活率降低,细胞凋亡率升高,AR组、SP组、SP+SB组、SP+DMSO组和DMSO组p-p38MAPK表达上调(P<0.05);与AR组比较,SP组、SP+SB组和SP+DMSO组LDH活性降低,细胞存活率升高,细胞凋亡率降低,p-p38MAPK表达上调(P<0.05);与SP组比较,SP+SB组、SB组和DMSO组LDH活性升高,细胞存活率降低,细胞凋亡率升高,p-p38MAPK表达下调(P<0.05).结论 七氟烷后处理可通过激活p38MAPK信号转导通路减轻乳鼠心肌细胞缺氧复氧损伤.     

阿米洛利预先给药对大鼠内毒素性急性肺损伤的影响

目的 探讨阿米洛利预先给药对大鼠内毒素性急性肺损伤的影响.方法 清洁级雄性SD大鼠32只,体重200～250 g,随机分为4组(n=8):对照组(C组)、急性肺损伤组(ALI组)、阿米洛利组(A组)和阿米洛利预先给药组(AL组).C组股静脉输注生理盐水3 ml,ALI组股静脉输注生理盐水1 ml、内毒素6 mg/kg,A组股静脉输注阿米洛利10 mg/kg、生理盐水2 ml,AL组股静脉输注阿米洛利10 mg/kg、内毒素6 mg/kg,输注速率均为0.05 ml/rain,给药间隔均为30 min.于输注内毒素结束后6 h时处死大鼠取肺,观察肺组织病理学,并行病理学评分,称重后计算肺湿干重比,检测髓过氧化物酶(MPO)活性,测定支气管肺泡灌洗液总蛋白、TNF-α和巨噬细胞炎性蛋白-2(MIP-2)的浓度,采用Western blot法检测肺组织钠氢交换体1(NHE1)、p38丝裂原活化蛋白激酶(p38MAPK)和细胞外信号调节激酶(ERK)的表达水平.结果 与C组比较,ALI组和AL组肺组织病理学评分、肺湿干重比、MPO活性、支气管肺泡灌洗液总蛋白、TNF-α和MIP-2浓度、肺组织NHE1、p38MAPK和ERK的表达水平明显升高(P＜0.01),A组上述指标差异无统计学意义(P＞0.05);与ALI组比较,AL组肺组织病理学评分、肺湿干重比、MPO活性、支气管肺泡灌洗液总蛋白、TNF-α和MIP-2浓度、肺组织NHE1和ERK的表达水平明显降低(P＜0.01),p38MAPK表达差异无统计学意义(P＞0.05).结论 阿米洛利预先给药可减轻大鼠内毒素性急性肺损伤,其机制可能与抑制ERK信号转导通路激活有关.     

p38丝裂原活化蛋白激酶信号转导通路在严重烧伤大鼠枯否细胞肿瘤坏死因子α和白细胞介素1β产生中的作用

目的 探讨p38丝裂原活化蛋白激酶(MAPK)信号转导通路在严重烧伤大鼠枯否细胞(KCs)促炎性细胞因子肿瘤坏死因子α(TNF-α)和白细胞介素1β(IL-1β)产生中的作用。方法 健康成年的雄性SD大鼠32只,随机分为：假烫组;假烫 SB203580组;烧伤对照组;烧伤 SB203580组,每组8只。假烫或烧伤24h后分离出肝脏KCs,培养18h后加入50ng／ml的LPS进行刺激,18h后取上清液,用酶联免疫吸附法(ELISA)测定TNF-α和IL-1β的含量,并收集KCs,实时逆转录聚合酶链反应检测KCs内TNF-α和IL-1β mRNA表达的改变,蛋白印迹(Western blot)法检测KCs中p38MAPK和JNK活性的变化。结果 烧伤大鼠分离出的KCs培养上清液中TNF-α和IL-1β含量、KCs中TNF-α和IL-1β mRNA的表达均较假烫组的明显增强,同时KCs中p38 MAPK活性和JNK活性升高,SB203580能显著抑制大鼠KCs上清液中TNF-α和IL-1β含量、KCs中TNF-α和IL-1β mRNA的表达和p38MAPK活性的升高,对JNK活性无影响。结论p38MAPK信号转导通路介导了严重烧伤大鼠KCs促炎性细胞因子TNF-α和IL-1β的产生。     

脊髓NMDA受体在大鼠糖尿病神经病理性痛中的作用

目的 评价脊髓NMDA受体在大鼠糖尿病神经病理性痛中的作用.方法 雌性Wistar大鼠,月龄3月,体重180～220 g,腹腔注射链脲菌素65 mg/kg制备糖尿病大鼠神经病理性痛模型.取模型制备成功的大鼠96只,随机分为3组(n=32):糖尿病神经病理性痛组(D组)、p38MAPK抑制剂组(I组)和NMDA受体阻断剂组(M组),另取32只正常大鼠作为对照组(C组).模型制备成功后每周一上午,I组和M组分别腹腔注射p38MAPK抑制剂SB203580 1 mg/kg、NMDA受体阻断剂MK-8011 mg/kg,1次/周,直至处死大鼠.各组分别于模型制备成功后第1、3、5、7周(T1～4)末随机取8只大鼠,采用yon Frey纤维丝测定双后足机械缩足反应阚值(MWT),采用肌电图仪测定左侧坐骨神经传导速度(NCV)后处死大鼠;取L3～6的背根神经节和脊髓,采用免疫组化法和Western blot法检测p38MAPK磷酸化水平,采用RT-PCR法检测NMDA受体1(NR1)mRNA表达.结果 与C组比较,D组、I组和M组T1～4时MWT降低,NCV减慢,p38MAPK磷酸化水平升高,NR1 mRNA表达上调(P<0.05);与D组比较,I组和M组MWT升高,NCV加快,T2～4时I组和M组p38MAPK磷酸化水平降低,M组NR1 mRNA表达下调(P<0.05).结论 脊髓NMDA受体激活可能通过p38MAPK信号通路参与大鼠糖尿病神经病理性痛的维持.     

斯伐他汀对糖尿病肾病大鼠肾小球系膜细胞p38信号通路的影响

目的研究糖尿病肾病大鼠肾小球系膜细胞p38丝裂原活化蛋白激酶（MAPK）的表达及斯伐他汀对其的影响。方法分别以高糖、糖基化终产物（AGE）及过氧化氢孵育糖尿病大鼠肾小球系膜细胞（RMC），Western印迹法检测RMC的p38MAPK和TGF—β蛋白表达，p38MAPK特异性抑制剂SB203580及斯伐他汀预处理对其影响。结果高糖、AGE及过氧化氢均可单独激活p38MAPK，增加RMC的磷酸化（P）p38MAPK和TGF—β的蛋白表达；SB203580显著抑制TGF—β的蛋白表达（P〈0．05）；斯伐他汀抑制p38MAPK的活化并减少TGF—β的蛋白表达（P〈0．05）。结论p38MAPK可能是糖尿病肾病发生的始动信号之一。斯伐他汀可能通过抑制p38MAPK磷酸化而减少TGF—β的蛋白表达。     

P38 mitogen-activated protein kinase inhibition attenuates pulmonary inflammatory response in a rat cardiopulmonary bypass model.

OBJECTIVE: Cardiopulmonary bypass (CPB) produces an inflammatory response associated with pulmonary dysfunction. P38 mitogen-activated protein kinase (P38MAPK) have been shown to mediate pulmonary inflammatory response after CPB, we examined the effect of SB203580, a specific p38 MAPK inhibitor, on CPB-induced pulmonary inflammatory response. METHODS: Sprague-Dawley rats (n=54) were randomized into three groups (each n=18): (1) S group, rats underwent sham CPB; (2) CPB group, rats underwent CPB; (3) SB group, rats underwent CPB plus pretreatment with SB203580 (10 mg/kg, i.v., 30 min before CPB). The lung samples were collected after 10 min, 60 min, and 150 min lung reperfusion (each n=6) in CPB group and SB group, and after 70 min, 120 min, and 210 min observation in S group as the control. RESULTS: The level of lung phospho-IkappaBalpha, nuclear factor (NF)-kappaB activity and activating protein (AP)-1 activity in CPB group was increased than S group. CPB resulted in increased pulmonary tissue tumor necrosis factor (TNF)-alpha and interleukin (IL)-1beta expression and production, increased pulmonary inflammatory response. The in vivo administration of SB203580 prevented up-regulation of lung-phosphorylated p38 MAP kinase, decreased pulmonary tissue level of proinflammatory cytokines expression and production, and reduced lung inflammation. CONCLUSIONS: These findings suggested that (1) p38 MAP kinase activation is one of the important aspects of the signaling event that mediate the release of TNF-alpha and IL-1beta and contributes to CPB-induced pulmonary inflammatory response, (2) SB203580 selectively inhibiting p38 MAP kinase activation efficaciously reduces pulmonary inflammatory response after CPB, and (3) p38 MAP kinase influence the activation of NF-kappaB in the lung during and after CPB.